{
  "extraction_date": "2025-12-23",
  "condition": "NEUROPATHIC_PAIN",
  "phase": "3",
  "priority": "Expansion",
  "total_studies": 7,
  "studies": [
    {
      "study_id": "CT_NCT05554146",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Pain Inflammation and Cannabis in HIV",
      "citation": "ClinicalTrials.gov NCTNCT05554146",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in Pain Severity Score"
        ],
        "outcome_measures": [
          "Change in Pain Severity Score"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05554146",
        "enrollment": 35,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05554146"
      }
    },
    {
      "study_id": "CT_NCT03372161",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Corticosteroid Lumbar Epidural Analgesia for Radiculopathy",
      "citation": "ClinicalTrials.gov NCTNCT03372161",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Mean Change From Baseline (Day 1) to Week 4 in the Mean Numeric Pain Rating Scale (NPRS) Average Pain Score in the Affected Leg"
        ],
        "outcome_measures": [
          "Mean Change From Baseline (Day 1) to Week 4 in the Mean Numeric Pain Rating Scale (NPRS) Average Pain Score in the Affected Leg"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03372161",
        "enrollment": 401,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03372161"
      }
    },
    {
      "study_id": "CT_NCT01555983",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Vaporized Cannabis and Spinal Cord Injury Pain",
      "citation": "ClinicalTrials.gov NCTNCT01555983",
      "publication_year": 2014,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Vaporization of Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Number of Participants Achieving a Reduction in Pain Intensity of 30% or More"
        ],
        "outcome_measures": [
          "Number of Participants Achieving a Reduction in Pain Intensity of 30% or More"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01555983",
        "enrollment": 42,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01555983"
      }
    },
    {
      "study_id": "CT_NCT07162454",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy",
      "citation": "ClinicalTrials.gov NCTNCT07162454",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Group 2. Cannabidiol and Urea 10% formula.",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Assessment of neuropathic pain."
        ],
        "outcome_measures": [
          "Assessment of neuropathic pain."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT07162454",
        "enrollment": 23,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT07162454"
      }
    },
    {
      "study_id": "CT_NCT00254761",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Effects of Smoked Marijuana on Neuropathic Pain",
      "citation": "ClinicalTrials.gov NCTNCT00254761",
      "publication_year": 2006,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Score on a series of pain scales (heat pain threshold, VAS intensity, VAS unpleasantness, pain relief, neuropathic pain scale)."
        ],
        "outcome_measures": [
          "Score on a series of pain scales (heat pain threshold, VAS intensity, VAS unpleasantness, pain relief, neuropathic pain scale)."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00254761",
        "enrollment": 28,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00254761"
      }
    },
    {
      "study_id": "CT_NCT03099005",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain",
      "citation": "ClinicalTrials.gov NCTNCT03099005",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Phase 1 - Numerical Pain Rating Scale (NPRS)"
        ],
        "outcome_measures": [
          "Phase 1 - Numerical Pain Rating Scale (NPRS)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03099005",
        "enrollment": 5,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03099005"
      }
    },
    {
      "study_id": "CT_NCT00872144",
      "study_type": "RCT",
      "condition": "NEUROPATHIC_PAIN",
      "study_title": "Sativex for Treatment of Chemotherapy Induced Neuropathic Pain",
      "citation": "ClinicalTrials.gov NCTNCT00872144",
      "publication_year": 2013,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in the NRS-PI from baseline to the final week of stable dose treatment)",
          "Participants gaining a 30% or greater reduction in the NRS-PI"
        ],
        "outcome_measures": [
          "Change in the NRS-PI from baseline to the final week of stable dose treatment)",
          "Participants gaining a 30% or greater reduction in the NRS-PI"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00872144",
        "enrollment": 16,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00872144"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 7,
    "pubmed_added": 0,
    "total_added": 7,
    "expansion_date": "2025-12-23T23:42:16.047074"
  }
}